Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 2
2020 4
2021 7
2022 9
2023 8
2024 10
2025 28
2026 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

72 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial.
Kaye KS, Belley A, Barth P, Lahlou O, Knechtle P, Motta P, Velicitat P. Kaye KS, et al. JAMA. 2022 Oct 4;328(13):1304-1314. doi: 10.1001/jama.2022.17034. JAMA. 2022. PMID: 36194218 Free PMC article. Clinical Trial.
IMPORTANCE: Cefepime/enmetazobactam is a novel beta-lactam/beta-lactamase inhibitor combination and a potential empirical therapy for resistant gram-negative infections. ...A total of 1.7% (9/516) of participants who received cefepime/enmetazobactam an …
IMPORTANCE: Cefepime/enmetazobactam is a novel beta-lactam/beta-lactamase inhibitor combination and a potential empirical ther …
Cefepime/Enmetazobactam: First Approval.
Keam SJ. Keam SJ. Drugs. 2024 Jun;84(6):737-744. doi: 10.1007/s40265-024-02035-2. Epub 2024 May 18. Drugs. 2024. PMID: 38761353
In February 2024, cefepime/enmetazobactam was approved in the USA for use in adults with complicated urinary tract infections (cUTI) including pyelonephritis, caused by susceptible strains of Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus m …
In February 2024, cefepime/enmetazobactam was approved in the USA for use in adults with complicated urinary tract infections …
Cefepime/Enmetazobactam.
Staten AR, Baker DE. Staten AR, et al. Hosp Pharm. 2024 Dec;59(6):606-613. doi: 10.1177/00185787241269112. Epub 2024 Aug 12. Hosp Pharm. 2024. PMID: 39465094 Free PMC article. Review.
Cefepime-enmetazobactam: first approved cefepime-beta- lactamase inhibitor combination for multi-drug resistant Enterobacterales.
Bhowmick T, Canton R, Pea F, Quevedo J, Santerre Henriksen A, Timsit JF, Kaye KS. Bhowmick T, et al. Future Microbiol. 2025 Mar;20(4):277-286. doi: 10.1080/17460913.2025.2468112. Epub 2025 Feb 26. Future Microbiol. 2025. PMID: 40007489 Free PMC article. Review.
In addition, if clinical data are supportive, cefepime-enmetazobactam has a potential role in the treatment of pathogens co-producing OXA-48 like enzymes along with ESBLs. ...ESBL is hard to treat because most drugs are no longer able to treat it. Cefepime- …
In addition, if clinical data are supportive, cefepime-enmetazobactam has a potential role in the treatment of pathogens co-pr …
Cefepime/Enmetazobactam: a microbiological, pharmacokinetic, pharmacodynamic, and clinical evaluation.
Darlow CA, Hope W, Dubey V. Darlow CA, et al. Expert Opin Drug Metab Toxicol. 2025 Jan-Feb;21(2):115-123. doi: 10.1080/17425255.2024.2427310. Epub 2024 Nov 10. Expert Opin Drug Metab Toxicol. 2025. PMID: 39508805 Free article. Review.
INTRODUCTION: Cefepime/enmetazobactam is a novel beta-lactam/beta-lactamase inhibitor (BL-BLI) combination with broad Gram-positive and -negative activity. ...AREAS COVERED: We describe the chemistry, pharmacodynamics, pharmacokinetics, toxicities, drug-drug interac …
INTRODUCTION: Cefepime/enmetazobactam is a novel beta-lactam/beta-lactamase inhibitor (BL-BLI) combination with broad Gram-pos …
In vitro activity of cefepime-enmetazobactam on carbapenem-resistant Gram negatives.
Bonnin RA, Jeannot K, Santerre Henriksen A, Quevedo J, Dortet L. Bonnin RA, et al. Clin Microbiol Infect. 2025 Feb;31(2):240-249. doi: 10.1016/j.cmi.2024.09.031. Epub 2024 Oct 5. Clin Microbiol Infect. 2025. PMID: 39374655 Free article.
OBJECTIVES: Cefepime-enmetazobactam is a new beta-lactam/betalactamase inhibitor combination with broad-spectrum activity against multidrug-resistant Enterobacterales, including extended-spectrum beta-lactamase producers. ...In vivo experiments have to be implemente …
OBJECTIVES: Cefepime-enmetazobactam is a new beta-lactam/betalactamase inhibitor combination with broad-spectrum activity agai …
Cefepime-Enmetazobactam: A Drug Review of a Novel Beta-Lactam/Beta-Lactamase Inhibitor.
Lanier C, Melton T, Covert K. Lanier C, et al. Ann Pharmacother. 2025 Jun;59(6):570-576. doi: 10.1177/10600280241279904. Epub 2024 Sep 27. Ann Pharmacother. 2025. PMID: 39329253 Review.
OBJECTIVE: To describe and analyze the pharmacodynamic and pharmacokinetic properties and clinical evidence supporting the efficacy and use of cefepime-enmetazobactam (FEP-EMT). DATA SOURCES: A literature search was conducted using MEDLINE and EMBASE databases (Janu …
OBJECTIVE: To describe and analyze the pharmacodynamic and pharmacokinetic properties and clinical evidence supporting the efficacy and use …
72 results